Business Context and Reporting Period
Company: BioCardia, Inc. (BCDA)
Filing Type: Form 8-K (Current Report)
Date of Report: April 30, 2025
Event Date: May 1, 2025
Business Focus: Development of autologous cell therapy for the treatment of heart failure.
Key Financial Metrics
This filing is a Regulation FD disclosure regarding a clinical trial milestone. The document does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data.
Material Changes
Clinical Trial Milestone: On May 1, 2025, the Company announced the enrollment of the first patient in the Phase III randomized, procedure placebo-controlled, double-blind CardiAMP HF II clinical trial.
Location: The enrollment occurred at BayCare Morton Plant Hospital in Clearwater, Florida.
Program: This trial evaluates the Company's lead autologous cell therapy program for heart failure.
Guidance, Outlook, and Risks
Management Commentary: The filing serves to disclose the press release attached as Exhibit 99.1, confirming the initiation of the pivotal Phase III trial.
Risks and Contingencies: No specific risks, contingencies, or unusual items are detailed within the text of this 8-K filing beyond the inherent uncertainties of clinical development implied by the trial announcement.
Investor Verification Checklist
- Verify the full text of the press release (Exhibit 99.1) for detailed trial design and enrollment targets.
- Review the Company's most recent 10-Q or 10-K for current cash runway and burn rate, as this 8-K contains no financial data.
- Monitor subsequent filings for patient enrollment progress and interim data readouts from the CardiAMP HF II trial.
- Confirm the regulatory status and protocol details of the CardiAMP HF II trial with the FDA or relevant clinical trial registries.